437 related articles for article (PubMed ID: 25605012)
1. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
Abdel Malek MA; Jagannathan S; Malek E; Sayed DM; Elgammal SA; Abd El-Azeem HG; Thabet NM; Driscoll JJ
Oncotarget; 2015 Feb; 6(5):3098-110. PubMed ID: 25605012
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.
Jagannathan S; Abdel-Malek MA; Malek E; Vad N; Latif T; Anderson KC; Driscoll JJ
Leukemia; 2015 Nov; 29(11):2184-91. PubMed ID: 26108695
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of GRP78 by HA15 promotes apoptosis of lung cancer cells accompanied by ER stress and autophagy.
Wu J; Wu Y; Lian X
Biol Open; 2020 Nov; 9(11):. PubMed ID: 33115703
[TBL] [Abstract][Full Text] [Related]
5. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
6. Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma.
Ninkovic S; Harrison SJ; Quach H
Expert Rev Hematol; 2020 Nov; 13(11):1201-1210. PubMed ID: 32990063
[TBL] [Abstract][Full Text] [Related]
7. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
[TBL] [Abstract][Full Text] [Related]
9. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
10. Kuanoniamine C stimulates bortezomib-induced cell death via suppression of glucose-regulated protein 78 in osteosarcoma.
Machihara K; Namba T
Biochem Biophys Res Commun; 2020 Jun; 527(1):289-296. PubMed ID: 32446382
[TBL] [Abstract][Full Text] [Related]
11. Targeting bortezomib-induced aggresome formation using vinorelbine enhances the cytotoxic effect along with ER stress loading in breast cancer cell lines.
Miyahara K; Kazama H; Kokuba H; Komatsu S; Hirota A; Takemura J; Hirasawa K; Moriya S; Abe A; Hiramoto M; Ishikawa T; Miyazawa K
Int J Oncol; 2016 Nov; 49(5):1848-1858. PubMed ID: 27601063
[TBL] [Abstract][Full Text] [Related]
12. Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells.
Moriya S; Komatsu S; Yamasaki K; Kawai Y; Kokuba H; Hirota A; Che XF; Inazu M; Gotoh A; Hiramoto M; Miyazawa K
Int J Oncol; 2015 Feb; 46(2):474-86. PubMed ID: 25422130
[TBL] [Abstract][Full Text] [Related]
13. The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma.
Nikesitch N; Rebeiro P; Ho LL; Pothula S; Wang XM; Khong T; Quek H; Spencer A; Lee CS; Roberts TL; Ling SCW
Cells; 2021 Dec; 10(12):. PubMed ID: 34943972
[No Abstract] [Full Text] [Related]
14. TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells.
Sisinni L; Maddalena F; Lettini G; Condelli V; Matassa DS; Esposito F; Landriscina M
Int J Oncol; 2014 Feb; 44(2):573-82. PubMed ID: 24297638
[TBL] [Abstract][Full Text] [Related]
15. A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.
Rasche L; Menoret E; Dubljevic V; Menu E; Vanderkerken K; Lapa C; Steinbrunn T; Chatterjee M; Knop S; Düll J; Greenwood DL; Hensel F; Rosenwald A; Einsele H; Brändlein S
Clin Cancer Res; 2016 Sep; 22(17):4341-9. PubMed ID: 27029491
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Kawaguchi T; Miyazawa K; Moriya S; Ohtomo T; Che XF; Naito M; Itoh M; Tomoda A
Int J Oncol; 2011 Mar; 38(3):643-54. PubMed ID: 21174067
[TBL] [Abstract][Full Text] [Related]
17. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
18. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
20. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
